Vetter Pharma International, a leading contract development and manufacturing organization, has launched the Open Innovation Challenge campaign to develop a future-focused and sustainable solutions for the injection of medicines. It is bringing together approximately 600 companies and research establishments. Promising ideas emanating from the initiative will be further pursued in the context of Vetter’s innovation process.
 
The challenge consists of multi-disciplinary teams participating in workshops and field-work with the theme Injection 2.0. Four groups comprising a total of 20 participants will include students, medical and economic professionals, and staff from the pharmaceutical service provider itself.
 
The initiative will apply Design Thinking, a user-centered innovation method that involves direct communication with actual users of injection systems, including professional caregivers and patients in an effort to create more purposeful injection processes. The campaign will continue until the end of September with the winning team receiving an award of EUR 10,000.
 
“As an innovative partner of the top 20 pharmaceutical and biotech companies worldwide, we feel it is our responsibility to introduce continuous improvements to the safety and comfort aspects of the injection process for users as well as enhancements to our service offering based around the injection of medicine. That is precisely what our Open Innovation Challenge is designed to do; benefit medical specialists and patients as well as offering our customers new and valuable insights,” said Dr. Claus Feussner, senior vice president Vetter Development Service.
 
In order to identify sustainable areas of innovation potential, the pharmaceutical service provider incorporates the Design Thinking method. The User-Centered Innovation (UCI) approach is based on direct integration of users from the first day of development work. For example, in the first field-work phase, participating teams will interview patients, doctors and professional caregivers in healthcare settings that include nursing homes, assisted living facilities, hospitals, and the home healthcare sector itself. The objective is to use this information to address patient’s conscious and subconscious needs and any problems that arise when interacting with injection systems on a regular basis.
 
Based on these results, user-oriented ideas for solutions can be generated. “In the future, the active integration of users into the pharmaceutical development process will take on increasing importance. Because most users have long since arrived in the digital world, they are expecting to see this megatrend applied to medical products as well. That is why we have been investing today for the future, as demonstrated by our Open Innovation Challenge. This initiative will not only strengthen our role as one of the world’s leading partners in the development and manufacture of injectable drugs, but also reinforce the competitive position of our clients in the global market,” said Oskar Gold, senior vice president key account management, marketing/corporate communications and customer project management, Vetter.